Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL753971 | 0.81 | ACHE (0.33) | KDM4EALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL207429 | 0.78 | CA2 (0.38) | ALDH1A1 | |
| SCHEMBL57641 | 0.78 | ALDH1A1 (0.41) | KDM4EALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL29213578 | 0.76 | CA2 (0.36) | — | |
| SCHEMBL7953267 | 0.72 | CA2 (0.33) | — | |
| SCHEMBL29160711 | 0.70 | SMN1; SMN2 (0.35) | KDM4EALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL455316 | 0.70 | — | — | |
| SCHEMBL887637 | 0.70 | GABRA1 (0.32) | — | |
| SCHEMBL158204 | 0.68 | — | — | |
| SCHEMBL7496964 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116802187-A | Organometallic compounds | 优米科尔股份公司及两合公司 | 2023-09-22 | — | — | CN | disclosed |
| US-8586612-B2 | Piperidinesulfonylureas and -thioureas, their preparation, their use and pharmaceutical compositions comprising them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2013-11-19 | — | — | US | disclosed |
| EP-1828131-B1 | PIPERIDINESULFONYLUREAS AND -THIOUREAS, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | SANOFI AVENTIS DEUTSCHLAND (DE) | 2008-06-04 | — | — | EP | disclosed |
| US-20080033016-A1 | Piperidinesulfonylureas and -thioureas, their preparation, their use and pharmaceutical compositions comprising them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-02-07 | — | — | US | disclosed |
| EP-1828131-A1 | PIPERIDINESULFONYLUREAS AND -THIOUREAS, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | Sanofi-Aventis Deutschland GmbH (DE) | 2007-09-05 | — | — | EP | disclosed |
| WO-2006063722-A1 | PIPERIDINESULFONYLUREAS AND -THIOUREAS, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2006-06-22 | — | — | WO | disclosed |
| US-4169106-A | Antiarrhythmic N,N'-bis(phenylcarbamoylalkyl)amidines | COOPER LABORATORIES, INC. (US) | 1979-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080033016-A1 | Piperidinesulfonylureas and -thioureas, their preparation, their use and pharmaceutical compositions comprising them | ATP2A1, ATP2A3, ATP2A2 | KDM4E 2378/4885ALDH1A1 1738/4885MAPK1 2721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.